source
- Gilead’s oral ulcerative colitis drug shows significant remission in Phase 2 trialGilead Sciences reported results from a Phase 2 trial of its oral ulcerative colitis drug emvistegrast. In the study, patients took a 200 mg daily dose for 12 weeks and achieved a 23% placebo-adju…
- Trump signs executive order to create NIH division and White House task force for women’s healthPresident Donald Trump signed an executive order on Monday establishing a new division within the National Institutes of Health and a White House task force focused on women’s health. The order dir…